Comparative Efficacy of Oral Calcitonin-Gene–Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Efficacy of Oral Calcitonin-Gene–Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-11
DOI
10.1007/s40261-020-00997-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ubrogepant for the treatment of migraine
- (2020) Martina Curto et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
- (2020) Bixi Gao et al. Frontiers in Pharmacology
- Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials
- (2020) Yanbo Yang et al. CNS DRUGS
- Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
- (2020) Eleonora De Matteis et al. Expert Review of Neurotherapeutics
- Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
- (2020) David Moreno-Ajona et al. CURRENT OPINION IN NEUROLOGY
- Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans
- (2020) Tessa de Vries et al. PHARMACOLOGY & THERAPEUTICS
- Gepants for the treatment of migraine
- (2019) Andrea Negro et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse
- (2019) Willem Sebastiaan van Hoogstraten et al. JOURNAL OF HEADACHE AND PAIN
- Therapeutic novelties in migraine: new drugs, new hope?
- (2019) Thien Phu Do et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
- (2019) Robert Croop et al. LANCET
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
- (2019) Richard B. Lipton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current and emerging evidence-based treatment options in chronic migraine: a narrative review
- (2019) Elio Clemente Agostoni et al. JOURNAL OF HEADACHE AND PAIN
- Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine
- (2019) Richard B. Lipton et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pathophysiology of Migraine
- (2019) Peter J. Goadsby et al. NEUROLOGIC CLINICS
- Ubrogepant for the Treatment of Migraine
- (2019) David W. Dodick et al. NEW ENGLAND JOURNAL OF MEDICINE
- 60th Annual Scientific Meeting American Headache Society® June 28-July 1, 2018 San Francisco Marriott Marquis San Francisco, CA
- (2018) HEADACHE
- The pathophysiology of migraine: implications for clinical management
- (2018) Andrew Charles LANCET NEUROLOGY
- Clinical features of migraine aura: Results from a prospective diary-aided study
- (2016) Michele Viana et al. CEPHALALGIA
- A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
- (2016) Tiffini Voss et al. CEPHALALGIA
- Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis
- (2016) Peiwei Hong et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis
- (2015) Chris Cameron et al. HEADACHE
- Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine
- (2015) R. B. Lipton et al. NEUROLOGY
- BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
- (2013) Ronald Marcus et al. CEPHALALGIA
- Triptan nonresponders: Do they exist and who are they?
- (2013) Michele Viana et al. CEPHALALGIA
- Efficacy, Safety, and Tolerability of Telcagepant in the Treatment of Acute Migraine: A meta-Analysis
- (2013) Xiao-ping Cui et al. Pain Practice
- Taking the Negative View of Current Migraine Treatments
- (2012) Peer Tfelt-Hansen et al. CNS DRUGS
- Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease
- (2012) Tony W. Ho et al. HEADACHE
- Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
- (2011) David J Hewitt et al. CEPHALALGIA
- Randomized Controlled Study of Telcagepant Plus Ibuprofen or Acetaminophen in Migraine
- (2011) David J. Hewitt et al. HEADACHE
- BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
- (2010) Hans-Christoph Diener et al. CEPHALALGIA
- Randomized, controlled trial of telcagepant over four migraine attacks
- (2010) Andrew P Ho et al. CEPHALALGIA
- Long-Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial
- (2010) Kathryn M. Connor et al. HEADACHE
- Randomized, controlled trial of telcagepant for the acute treatment of migraine
- (2009) K. M. Connor et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now